Shares of NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY – Get Rating) passed above its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $0.00 and traded as high as $2.49. NovaBay Pharmaceuticals shares last traded at $2.34, with a volume of 228,055 shares.
NovaBay Pharmaceuticals Stock Up 4.5 %
The stock has a market capitalization of $4.35 million, a P/E ratio of -13.76 and a beta of 3.47.
Insider Buying and Selling
In other NovaBay Pharmaceuticals news, insider Jeffrey Kunin sold 291,368 shares of NovaBay Pharmaceuticals stock in a transaction on Wednesday, September 14th. The stock was sold at an average price of $0.16, for a total transaction of $46,618.88. Following the completion of the transaction, the insider now directly owns 208,632 shares of the company’s stock, valued at $33,381.12. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 1.80% of the stock is owned by company insiders.
Institutional Inflows and Outflows
About NovaBay Pharmaceuticals
NovaBay Pharmaceuticals, Inc, a pharmaceutical company, develops and sells eyecare and skincare products in the United States and internationally. It offers Avenova, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products under the NeutroPhase and PhaseOne brands.
- Get a free copy of the StockNews.com research report on NovaBay Pharmaceuticals (NBY)
- After Nixing its 13% Dividend, Is Lumen Technologies Okay To Own?
- The Sell-Side Caps Gains In Dick’s Sporting Goods
- Cisco Systems Hopes Restructuring Cuts Costs to Drive Revenue
- Want to Get a 10% Dividend Yield, Look Here
- Stock-ing Stuffers: 3 Attractive Stocks Trading Around $10
Receive News & Ratings for NovaBay Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.